Kabra Drugs
Healthcare
524322 BSE
₹15.98
Close ·
- P/E
- 4.99
Close 4 Nov 2026 ₹15.98 −3.39 −17.5% 1Y
Start ₹19.37
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures at the close · EPS basis: Standalone · TTM
- ROCE
- 20.80%
- Debt to Equity
- 0.03
- EPS (TTM)
- ₹3.20
- Book Value
- ₹12.49
- Market Cap
- —
- P/E (TTM)
- 4.99
- P/B
- 1.28
- ROE
- 18.30%
- Dividend Yield
- 0.00%
- EBITDA
- ₹5.80 Cr
- 52W High
- ₹35.52
- 52W Low
- ₹15.25
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
49 Average
Data confidence 95/100
Category scores
- Quality
- 29
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 63
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 48
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 7
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has delivered good profit growth of 96.8% CAGR over last 5 years
Weaknesses
2- Company has a low return on equity of 7.79% over last 3 years.
- Company has high debtors of 279 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 5 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Strong Bearish
Bearish
12
Neutral
5
Bullish
2
Moving Averages
Strong Bearish
Bearish
10
Neutral
0
Bullish
0
Key readings
- RSI (14)
- 37.52
- Neutral
- MACD (12,26,9)
- −0.91
- Bullish
- SMA (50)
- 18.62
- Bearish
- SMA (200)
- 24.26
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +24.98% |
|---|---|
| 5Y | Zero base |
| 3Y | Zero base |
| 1Y | Zero base |
| TTM | Tiny base |
Net profit
| 10Y | Zero base |
|---|---|
| 5Y | Zero base |
| 3Y | Zero base |
| 1Y | Turned to profit |
| TTM | Turned to profit |
Operating cash flow
| 10Y | Turned negative |
|---|---|
| 5Y | Turned negative |
| 3Y | Turned negative |
| 1Y | Outflow widened by ₹4 Cr |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +5.38 pp |
|---|---|
| 5Y | No sales |
| 3Y | No sales |
| 1Y | No sales |
| TTM | +30.16 pp |
Revenue by year
| Mar 2017 | ₹8.00 Cr |
|---|---|
| Mar 2018 | ₹2.00 Cr |
| Mar 2019 | ₹0.00 Cr |
| Mar 2020 | ₹0.00 Cr |
| Mar 2021 | ₹0.00 Cr |
| Mar 2022 | ₹0.00 Cr |
| Mar 2023 | ₹0.00 Cr |
| Mar 2024 | ₹0.00 Cr |
| Mar 2025 | ₹0.00 Cr |
| Mar 2026 | ₹93.00 Cr |
Net profit by year
| Mar 2017 | ₹0.00 Cr |
|---|---|
| Mar 2018 | −₹2.00 Cr |
| Mar 2019 | ₹0.00 Cr |
| Mar 2020 | ₹0.00 Cr |
| Mar 2021 | ₹0.00 Cr |
| Mar 2022 | ₹0.00 Cr |
| Mar 2023 | ₹0.00 Cr |
| Mar 2024 | −₹1.00 Cr |
| Mar 2025 | −₹1.00 Cr |
| Mar 2026 | ₹5.00 Cr |
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.15 | 19.76 | 30.42 | 35.41 | 46.22 |
| Expenses | 0.12 | 0.13 | 0.11 | 0.37 | 0.55 | 0.4 | 0.53 | 0.24 | 7.67 | 17.72 | 27.99 | 34.07 | 43.43 |
| Operating Profit | −0.12 | −0.13 | −0.11 | −0.37 | −0.55 | −0.4 | −0.53 | −0.24 | −0.52 | 2.04 | 2.43 | 1.34 | 2.79 |
| OPM % | — | — | — | — | — | — | — | — | −7.27% | 10.32% | 7.99% | 3.78% | 6.04% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.64 | 0.02 | 0.18 | 0.18 | 0.11 | 0.08 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.02 | 0.02 |
| PBT | −0.12 | −0.13 | −0.11 | −0.37 | −0.55 | −0.4 | −0.53 | 0.39 | −0.5 | 2.21 | 2.6 | 1.42 | 2.84 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 16.74% | 1.54% | 25.35% | 25.35% |
| Net Profit | −0.12 | −0.13 | −0.11 | −0.37 | −0.55 | −0.4 | −0.54 | 0.39 | −0.5 | 1.84 | 2.57 | 1.06 | 2.12 |
| EPS (₹) | −0.27 | −0.3 | −0.25 | −0.84 | −1.25 | −0.4 | −0.54 | 0.16 | −0.21 | 0.78 | 1.08 | 0.45 | 0.89 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8 | 10 | 8 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 93 | 132 |
| Expenses | 8 | 9 | 7 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 87 | 123 |
| Operating Profit | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | −1 | −2 | 5 | 9 |
| OPM % | 6% | 4.7% | 6% | −57% | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | — | — | 6% | 7% |
| Other Income | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | −2 | 0 | 0 | 0 | 0 | 0 | −1 | −1 | 6 | 9 |
| Tax % | 36% | 40% | 7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | — |
| Net Profit | 0 | 0 | 0 | −2 | 0 | 0 | 0 | 0 | 0 | −1 | −1 | 5 | 8 |
| EPS (₹) | 0.16 | 0.07 | 0.3 | −5.38 | −0.36 | −0.14 | −0.41 | −0.43 | −0.77 | −1.69 | −0.46 | 2.09 | 3.2 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 24 | 24 |
| Reserves | −2 | −2 | −2 | −4 | −4 | −4 | −5 | −5 | −5 | −3 | 1 | 6 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 |
| Other Liabilities | 3 | 4 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 56 |
| Total Liabilities | 9 | 9 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
| Fixed Assets | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 6 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 85 |
| Total Assets | 9 | 9 | 6 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 25 | 86 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −5 | −9 |
| Investing | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 |
| Financing | 1 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 3 | 23 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 19 | −11 |
| Free Cash Flow | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | −5 | −10 |
| CFO/OP | −38 | 67 | 73 | 10 | 138 | 100 | 167 | 72 | 100 | 28 | 274 | −173 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 198 | 204 | 141 | 254 | — | — | — | — | — | — | — | 279 |
| Inventory Days | 26 | 16 | 17 | 0 | — | — | — | — | — | — | — | 0 |
| Days Payable | 130 | 140 | 97 | — | — | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 94 | 80 | 61 | 254 | — | — | — | — | — | — | — | 279 |
| Working Capital Days | 86 | 70 | 34 | −28 | — | — | — | — | — | — | — | 66 |
| ROCE % | 4% | 4% | 7% | −44% | −19% | −9% | −27% | −29% | −53% | −43% | −8% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kabra Drugs insights
61 extracted metrics across FY08–FY27.
Documents
- Intimation 30 Oct 2026
- General announcements 12 Oct 2026
Frequently Asked Questions about Kabra Drugs
What does Kabra Drugs Ltd do?
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.
Where is Kabra Drugs Ltd (KABRADG) listed?
Kabra Drugs Ltd trades under code 524322 on the BSE.
Which sector does Kabra Drugs Ltd belong to?
Kabra Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd trades at a PE ratio of 4.99 as of 4 Nov 2026, on earnings per share of ₹3.2, against a book value of ₹12.49 per share.
What is the 52-week high and low of Kabra Drugs Ltd?
Over the last 52 weeks Kabra Drugs Ltd has traded between ₹15.25 and ₹35.52 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Kabra Drugs Ltd?
Kabra Drugs Ltd reported a return on equity of 18.30%. Its debt-to-equity ratio is 0.03.
Company Information
Incorporated in 1989, Kabra Drugs Ltd deals in pharmaceutical products, biological API’s and biochemicals.
Website kabradrugs.com
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524322.md for Kabra Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.